Pfizer raises annual profit forecast

Pfizer raised its full-year adjusted profit forecast to $2.90-$3.10 per share for 2025, following a strong second quarter where adjusted EPS of 78 cents and total sales of $14.65 billion significantly surpassed analyst expectations. The outperformance was driven by robust demand for key drugs Vyndaqel and Eliquis, along with a favorable foreign exchange impact, leading to a 2.8% premarket stock increase. Despite the positive results, the company continues to navigate industry pressures related to drug pricing and potential tariffs.

Analysis

Pfizer has demonstrated significant operational strength in its second-quarter results, substantially beating analyst expectations on both revenue and profit. The company reported total sales of $14.65 billion against a forecast of $13.56 billion and delivered an adjusted EPS of 78 cents, well above the consensus estimate of 58 cents. This outperformance was primarily fueled by stronger-than-expected sales from its heart disease drug Vyndaqel ($1.62 billion) and blood thinner Eliquis ($2.0 billion), along with a $22 million favorable impact from foreign currency exchange. Consequently, Pfizer has raised its full-year 2025 adjusted profit forecast to a range of $2.90 to $3.10 per share, up from $2.80 to $3.00. Notably, this upgraded guidance includes and absorbs a 20-cent per share one-time charge, indicating even stronger underlying business momentum. However, the company continues to navigate significant industry headwinds, including political pressure on drug pricing, potential 15% EU tariffs which it believes it can mitigate by leveraging its U.S. manufacturing sites, and a highlighted political risk to its vaccine portfolio, which constitutes 20% of revenues.

Key Decisions for Investors

• The significant earnings and revenue beat, driven by outperformance in key drugs Eliquis and Vyndaqel, strengthens the bull case for the stock.
• Investors should note the raised full-year guidance is particularly robust as it absorbs a 20-cent one-time charge, suggesting strong underlying operational momentum heading into the rest of the year.
• Despite the positive results, it is crucial to monitor political and regulatory risks, specifically drug pricing pressures and potential policy shifts impacting the vaccine business, which accounts for a material 20% of revenue.